How do you balance short-course ADT in unfavorable intermediate risk prostate cancer patients with cardiac comorbidities?  

One paper that addresses the topic was published in the Red Journal in 2016 (Rose et al., PMID 27788950). This retrospective analysis attempted to answer the question of which patients would derive disease-specific mortality benefit from the addition of ADT. Patients included in this analysis were f...